Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Colorcon
Express Scripts
Mallinckrodt
Moodys

Last Updated: August 19, 2022

Investigational Drug Information for Lumicitabine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Lumicitabine?

Lumicitabine is an investigational drug.

There have been 7 clinical trials for Lumicitabine. The most recent clinical trial was a Phase 2 trial, which was initiated on October 25th 2016.

The most common disease conditions in clinical trials are Virus Diseases, Respiratory Syncytial Virus Infections, and Respiratory Sounds. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].

There are twelve US patents protecting this investigational drug and one hundred and seventy-two international patents.

Recent Clinical Trials for Lumicitabine
TitleSponsorPhase
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human MetapneumovirusJanssen Research & Development, LLCPhase 2
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1

See all Lumicitabine clinical trials

Clinical Trial Summary for Lumicitabine

Top disease conditions for Lumicitabine
Top clinical trial sponsors for Lumicitabine

See all Lumicitabine clinical trials

US Patents for Lumicitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lumicitabine See Plans and Pricing Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA) See Plans and Pricing
Lumicitabine See Plans and Pricing RSV antiviral pyrazolo- and triazolo-pyrimidine compounds Janssen Sciences Ireland UC (Little Island, Co Cork, IE) See Plans and Pricing
Lumicitabine See Plans and Pricing Antiviral compounds Alios BioPharma, Inc. (South San Francisco, CA) See Plans and Pricing
Lumicitabine See Plans and Pricing Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (South San Francisco, CA) See Plans and Pricing
Lumicitabine See Plans and Pricing Methods of preparing substituted nucleoside analogs ALIOS BIOPHARMA, INC. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lumicitabine

Drugname Country Document Number Estimated Expiration Related US Patent
Lumicitabine Australia AU2015280234 2034-06-24 See Plans and Pricing
Lumicitabine Canada CA2952959 2034-06-24 See Plans and Pricing
Lumicitabine China CN106604734 2034-06-24 See Plans and Pricing
Lumicitabine Eurasian Patent Organization EA201692537 2034-06-24 See Plans and Pricing
Lumicitabine European Patent Office EP3160475 2034-06-24 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Colorcon
Express Scripts
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.